TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With ECOG Performance Status by 6-months Time Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revision and reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of the Study Questionnaires and Auricular Acupressure Protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Potential Adverse Events associated with Auricular Acupressure
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of MedTec S-frame head and neck immobilization system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control Preferences Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decision Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in pain pressure thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Perceived
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune responses adequate to be protective
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of adverse events of CTCAE grade III-V
Endpoint domain: Adverse events/effects
Primary endpoint: Product Performance at Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of peripheral T cell immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Electrical impedance values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Extent of Presence/Absence of Epithelial Tongue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mature oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ultrasound measurements of the zygomaticus major muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychometric assessments of improvements in facial appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Angiographic target vessel failure (TVF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: OCT anterior topography validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discontinuation due to all causes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Breast Epithelial Cell Proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Short Musculoskeletal Function Assessment (SMFA) - Dysfunction Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in brain DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of manic and depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of self-donated units of blood collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Therapeutic Cure of Scabies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline lipoprotein(a), lipoprotein particle number, and lipoprotein size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in baseline low-density lipoprotein (LDL) peak size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Conversion from Mild Cognitive Impairment to Alzheimer's Disease
Endpoint domain: Mortality/survival
Primary endpoint: 12 month cumulative COC discontinuation probabilities
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: radiographic distance between crestal bone and implant platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal Fold Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who successfully set up the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who successfully pass the training program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Non-displaceable Binding Potential (BP-ND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of CKD-344
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: implant success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of Patients Receiving GI Consult for FOBT+ Results
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Patients Receiving GI Consult Plus Anatomic Workup for FOBT+ Results
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wheal and flare reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in flow mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FMD post reperfusion lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distance and near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring for all Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Faecal sIgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cerebral perfusion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oximetry changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trans-cranial doppler velocity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Embolization with LC Bead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Liver Function Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Efficacy of trabectedin and doxorubicin combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glucose Monitoring Adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Medication Adherence Via MEMS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinician Rated Depression (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression on the CGI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with symptomatic or asymptomatic VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Degree of displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrarticular stepoff
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degenerative osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Streptococcus mutans levels (CFU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Conductance Algesimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection rates after cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent change in lung cancer screening awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent change in knowledge of eligibility guidelines for screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change in knowledge of benefits of early detection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of persistent pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain outcomes
Primary endpoint: retention/completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: drop out rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: randomization, recruitment rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success of Blinding
Endpoint domain: Adverse events/effects
Primary endpoint: Left ventricular dP/dt Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Revision (non-survival) rate
Endpoint domain: Mortality/survival
Primary endpoint: Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worse COVID-19 outcome
Endpoint domain: Mortality/survival
Primary endpoint: CD4 lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Days of exercise according to prescription (exercise log)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of exercise according to prescription (heart rate monitor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient numbers in the different FAB subtypes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of Suicide Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Severe Acute Oral Mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Relief of Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intra-operative bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's assessment according to the Facial Wrinkle Scale (FWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in 24 hour pad weight test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression measured with CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective tumor response (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hemostasis at the target blood oozing site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of differentially expressed genes associated with acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Myoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of the vaginal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of the rectal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of the placental microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of the uterine microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of the neonatal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Sterilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HIV knowledge accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in mean Pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident cervical infection with HPV-16 and/or HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of multiple, simultaneously occurring symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Parameters (Exposure) of Ifetroban and Ifetroban Acylglucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Parameters (Concentration) of Ifetroban and Ifetroban Acylglucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term outcomes following cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Luteinizing Hormone (LH) Pulse Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety of ublituximab in combination with ibrutinib
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with at least a 20% maintained reduction in Baseline time spent off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One or More Tier 1 Adverse Events (AEs) During the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinued Study Drug Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Feasibility
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Measure of synovial fluid biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in nasopharyngeal SARS-CoV-2 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of other infectious agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduced risk drinking
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced episodes of unprotected intercourse
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in average stool form score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of postoperative ileus and obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Participants With Clinical Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of HCV DAA therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Side-to-side differences in the unilateral seated shot put test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side-to-side differences in the upper quarter Y balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of the Arm, Shoulder and Hand (sports module)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Dizziness Handicap Inventory (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Computerized Dynamic Posturography (CDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of genomic markers that can predict uterine atony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Antibody response to hepatitis A and hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of CMR in clinical practice
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Instrumental activities of daily living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Vancouver Scar Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in quick Disability of the Arm, Shoulder and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Impact of CSF biomarker testing on management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Symptomatic Ischemic Stroke and Unrecognized Brain Infarction by Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite of Adjudicated Major Bleeding and Clinically Relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with undetectable plasma viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Myocardial T2*
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Compliance-to-intervention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Caregiver's Parental Reflective Function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freedom From Device or Procedure Related Death or Reintervention
Endpoint domain: Mortality/survival
Primary endpoint: Geometric Mean Ratio of Cmax of Cytochrome P450 Probe Substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio of AUC (0-inf) of Cytochrome P450 Probe Substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio of AUC (0-24) of Cytochrome P450 Probe Substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythropoietin Requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 1-year combined primary endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Survival to ECMO ICU discharge
Endpoint domain: Mortality/survival
Primary endpoint: Sagittal spinal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DMFS (Decayed, Missing, Filled Surfaces)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dft (decayed teeth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dfs (decayed surfaces)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Control Rate at 9 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of the IMP
Endpoint domain: Adverse events/effects
Primary endpoint: expression of SGSH in total leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: safety of the IMP
Endpoint domain: Adverse events/effects
Primary endpoint: Change in area under curve for Low-density lipoprotein cholesterol (LDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to enroll a minimum of 10% of all eligible neonates per year at each site
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fewer than 20% randomized subjects with protocol violations in High CPAP arm
Endpoint domain: Adverse events/effects
Primary endpoint: Fewer than 20% randomized subjects with protocol violations in NIPPV arm
Endpoint domain: Adverse events/effects
Primary endpoint: Fewer than 20% of enrolled (consented, but pre-randomization) subjects with protocol violations
Endpoint domain: Adverse events/effects
Primary endpoint: Epicardial potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epicardial electrograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epicardial activation and recovery sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of Cefoxitin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average of Worst Anal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes